Does TOSITUMOMAB I-131 Cause Second primary malignancy? 22 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 22 reports of Second primary malignancy have been filed in association with TOSITUMOMAB I-131. This represents 57.9% of all adverse event reports for TOSITUMOMAB I-131.
22
Reports of Second primary malignancy with TOSITUMOMAB I-131
57.9%
of all TOSITUMOMAB I-131 reports
21
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From TOSITUMOMAB I-131?
Of the 22 reports, 21 (95.5%) resulted in death.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOSITUMOMAB I-131. However, 22 reports have been filed with the FAERS database.
What Other Side Effects Does TOSITUMOMAB I-131 Cause?
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)